GlobeNewswire Inc.··Not SpecifiedTherini Bio Advances Novel Eye Disease Treatment as Phase 1b Trial Begins
Therini Bio initiates Phase 1b trial of THN391 for diabetic macular edema. Results expected Q4 2026.
MRKLLYSNYdiabetic macular edemabispecific antibody